Remove DEA Remove Information Remove Safety
article thumbnail

Court: DEA Must Explain Its Failure to Act Upon Pending Marijuana Cultivation Applications

NORML

” To date, however, the agency has neither affirmed or denied any of the 26 applicants that have sought the DEA’s permission for a federal cultivation license. Read NORML’s new op-ed, “Three years ago the DEA said they would remove roadblocks to cannabis research — they still haven’t, here.).

DEA 243
article thumbnail

Intoxicating Hemp Swindle

Project CBD

Devitt expresses serious safety concerns. In response to its growing popularity, the DEA announced in 2016 that kratom would be placed in the restrictive Schedule I along with cannabis. However, the following year the DEA put off its decision pending further public commentary.

Hemp 232
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Scientists Sue DEA as it Drags its Feet and Hampers Cannabis Research

WeedAdvisor

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety.

DEA 111
article thumbnail

DEA Approves Cocaine Derivative for Parkinson’s Research. Why Not Cannabis?

Veriheal

But recent news of the DEA’s approval of a cocaine derivative for Parkinson’s disease research has left us scratching our heads. After receiving a petition three years prior, the DEA finally answered with action, making plans to deschedule [18F]FP-CIT , a controlled substance derived from cocaine. .”

DEA 98
article thumbnail

Congressional Committee to Hold Marijuana Legislative Hearing This Wednesday

NORML

Strait, Senior Policy Advisor, Diversion Control Division, Drug Enforcement Administration (DEA). More information on the hearing can be found at the subcommittee’s website here. Read additional information about the MORE Act here. Witnesses will be: Matthew J. Douglas Throckmorton, M.D., Volkow, M.D.,

article thumbnail

Chacruna: Ayahuasca FOIA Requests Reveal Increased Ayahuasca Seizures, Lack of Due Process and Government Secrecy

Cannabis Law Report

On March 16, 2021, lawyers for CEC and Chacruna simultaneously filed Freedom of Information Act (“FOIA”) requests on U.S. Drug Enforcement Agency (“DEA”). This is useful information to understand that non-ayahuasca DMT appears to be a much more common seizure at the border. Customs Border Patrol (“CBP”) and U.S.

DEA 97
article thumbnail

Is The DEA Poised To Regulate Telepharmacy?

Cannabis Law Report

On November 16, 2021, the Drug Enforcement Agency (DEA) issued an advance notice of proposed rulemaking , exploring whether or not to create new federal regulations governing the practice of telepharmacy. The DEA’s notice provides the industry with an opportunity to provide insight and feedback that may help shape the new regulations.

DEA 52